img

Global Drugs for Metabolic Disorders Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Drugs for Metabolic Disorders Market Research Report 2024

Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
According to Mr Accuracy reports new survey, global Drugs for Metabolic Disorders market is projected to reach US$ 160970 million in 2029, increasing from US$ 82150 million in 2022, with the CAGR of 10.1% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for Metabolic Disorders market research.
The Metabolic Disorders Drugs market refers to the pharmaceuticals and medications used for the treatment of disorders related to metabolism, such as diabetes, obesity, hyperlipidemia, and thyroid disorders. This market encompasses various therapeutic areas including antidiabetic drugs, lipid-lowering agents, and thyroid hormone replacements. The Metabolic Disorders Drugs market has been experiencing significant growth due to factors such as the increasing prevalence of metabolic disorders globally, sedentary lifestyles, and unhealthy dietary habits. Key players in the market include pharmaceutical companies, biotechnology firms, and generic drug manufacturers. Geographically, North America currently holds a significant market share, followed by Europe. However, the market in Asia Pacific is expected to witness substantial growth in the coming years, driven by the rising incidence of metabolic disorders and improving healthcare infrastructure.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Drugs for Metabolic Disorders market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Segment by Type
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other

Segment by Application


Hospital
Retail Pharmacy

Consumption by Region


North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Drugs for Metabolic Disorders report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Drugs for Metabolic Disorders Market Overview
1.1 Product Overview and Scope of Drugs for Metabolic Disorders
1.2 Drugs for Metabolic Disorders Segment by Type
1.2.1 Global Drugs for Metabolic Disorders Market Value Comparison by Type (2024-2034)
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Drugs for Metabolic Disorders Segment by Application
1.3.1 Global Drugs for Metabolic Disorders Market Value by Application: (2024-2034)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Drugs for Metabolic Disorders Market Size Estimates and Forecasts
1.4.1 Global Drugs for Metabolic Disorders Revenue 2018-2029
1.4.2 Global Drugs for Metabolic Disorders Sales 2018-2029
1.4.3 Global Drugs for Metabolic Disorders Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Drugs for Metabolic Disorders Market Competition by Manufacturers
2.1 Global Drugs for Metabolic Disorders Sales Market Share by Manufacturers (2018-2024)
2.2 Global Drugs for Metabolic Disorders Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Drugs for Metabolic Disorders Average Price by Manufacturers (2018-2024)
2.4 Global Drugs for Metabolic Disorders Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Drugs for Metabolic Disorders, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Metabolic Disorders, Product Type & Application
2.7 Drugs for Metabolic Disorders Market Competitive Situation and Trends
2.7.1 Drugs for Metabolic Disorders Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Drugs for Metabolic Disorders Players Market Share by Revenue
2.7.3 Global Drugs for Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Drugs for Metabolic Disorders Retrospective Market Scenario by Region
3.1 Global Drugs for Metabolic Disorders Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Drugs for Metabolic Disorders Global Drugs for Metabolic Disorders Sales by Region: 2018-2029
3.2.1 Global Drugs for Metabolic Disorders Sales by Region: 2018-2024
3.2.2 Global Drugs for Metabolic Disorders Sales by Region: 2024-2029
3.3 Global Drugs for Metabolic Disorders Global Drugs for Metabolic Disorders Revenue by Region: 2018-2029
3.3.1 Global Drugs for Metabolic Disorders Revenue by Region: 2018-2024
3.3.2 Global Drugs for Metabolic Disorders Revenue by Region: 2024-2029
3.4 North America Drugs for Metabolic Disorders Market Facts & Figures by Country
3.4.1 North America Drugs for Metabolic Disorders Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Drugs for Metabolic Disorders Sales by Country (2018-2029)
3.4.3 North America Drugs for Metabolic Disorders Revenue by Country (2018-2029)
3.4.4 the United States
3.4.5 Canada
3.5 Europe Drugs for Metabolic Disorders Market Facts & Figures by Country
3.5.1 Europe Drugs for Metabolic Disorders Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Drugs for Metabolic Disorders Sales by Country (2018-2029)
3.5.3 Europe Drugs for Metabolic Disorders Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Metabolic Disorders Market Facts & Figures by Country
3.6.1 Asia Pacific Drugs for Metabolic Disorders Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Drugs for Metabolic Disorders Sales by Country (2018-2029)
3.6.3 Asia Pacific Drugs for Metabolic Disorders Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Drugs for Metabolic Disorders Market Facts & Figures by Country
3.7.1 Latin America Drugs for Metabolic Disorders Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Drugs for Metabolic Disorders Sales by Country (2018-2029)
3.7.3 Latin America Drugs for Metabolic Disorders Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Drugs for Metabolic Disorders Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Metabolic Disorders Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Drugs for Metabolic Disorders Sales by Country (2018-2029)
3.8.3 Middle East and Africa Drugs for Metabolic Disorders Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Metabolic Disorders Sales by Type (2018-2029)
4.1.1 Global Drugs for Metabolic Disorders Sales by Type (2018-2024)
4.1.2 Global Drugs for Metabolic Disorders Sales by Type (2024-2029)
4.1.3 Global Drugs for Metabolic Disorders Sales Market Share by Type (2018-2029)
4.2 Global Drugs for Metabolic Disorders Revenue by Type (2018-2029)
4.2.1 Global Drugs for Metabolic Disorders Revenue by Type (2018-2024)
4.2.2 Global Drugs for Metabolic Disorders Revenue by Type (2024-2029)
4.2.3 Global Drugs for Metabolic Disorders Revenue Market Share by Type (2018-2029)
4.3 Global Drugs for Metabolic Disorders Price by Type (2018-2029)
5 Segment by Application
5.1 Global Drugs for Metabolic Disorders Sales by Application (2018-2029)
5.1.1 Global Drugs for Metabolic Disorders Sales by Application (2018-2024)
5.1.2 Global Drugs for Metabolic Disorders Sales by Application (2024-2029)
5.1.3 Global Drugs for Metabolic Disorders Sales Market Share by Application (2018-2029)
5.2 Global Drugs for Metabolic Disorders Revenue by Application (2018-2029)
5.2.1 Global Drugs for Metabolic Disorders Revenue by Application (2018-2024)
5.2.2 Global Drugs for Metabolic Disorders Revenue by Application (2024-2029)
5.2.3 Global Drugs for Metabolic Disorders Revenue Market Share by Application (2018-2029)
5.3 Global Drugs for Metabolic Disorders Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Merck Drugs for Metabolic Disorders Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.2.4 Novartis Drugs for Metabolic Disorders Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Takeda Pharmaceutical
6.3.1 Takeda Pharmaceutical Corporation Information
6.3.2 Takeda Pharmaceutical Description and Business Overview
6.3.3 Takeda Pharmaceutical Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Takeda Pharmaceutical Drugs for Metabolic Disorders Product Portfolio
6.3.5 Takeda Pharmaceutical Recent Developments/Updates
6.4 Astra Zeneca
6.4.1 Astra Zeneca Corporation Information
6.4.2 Astra Zeneca Description and Business Overview
6.4.3 Astra Zeneca Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Astra Zeneca Drugs for Metabolic Disorders Product Portfolio
6.4.5 Astra Zeneca Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.5.4 Boehringer Ingelheim Drugs for Metabolic Disorders Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 KOWA
6.6.1 KOWA Corporation Information
6.6.2 KOWA Description and Business Overview
6.6.3 KOWA Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.6.4 KOWA Drugs for Metabolic Disorders Product Portfolio
6.6.5 KOWA Recent Developments/Updates
6.7 Kythera
6.6.1 Kythera Corporation Information
6.6.2 Kythera Description and Business Overview
6.6.3 Kythera Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Kythera Drugs for Metabolic Disorders Product Portfolio
6.7.5 Kythera Recent Developments/Updates
6.8 Fuji yakuhin
6.8.1 Fuji yakuhin Corporation Information
6.8.2 Fuji yakuhin Description and Business Overview
6.8.3 Fuji yakuhin Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.8.4 Fuji yakuhin Drugs for Metabolic Disorders Product Portfolio
6.8.5 Fuji yakuhin Recent Developments/Updates
6.9 LG Life Science
6.9.1 LG Life Science Corporation Information
6.9.2 LG Life Science Description and Business Overview
6.9.3 LG Life Science Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.9.4 LG Life Science Drugs for Metabolic Disorders Product Portfolio
6.9.5 LG Life Science Recent Developments/Updates
6.10 Metsubishi Tanabe Pharma
6.10.1 Metsubishi Tanabe Pharma Corporation Information
6.10.2 Metsubishi Tanabe Pharma Description and Business Overview
6.10.3 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales, Revenue and Gross Margin (2018-2024)
6.10.4 Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product Portfolio
6.10.5 Metsubishi Tanabe Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Metabolic Disorders Industry Chain Analysis
7.2 Drugs for Metabolic Disorders Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Metabolic Disorders Production Mode & Process
7.4 Drugs for Metabolic Disorders Sales and Marketing
7.4.1 Drugs for Metabolic Disorders Sales Channels
7.4.2 Drugs for Metabolic Disorders Distributors
7.5 Drugs for Metabolic Disorders Customers
8 Drugs for Metabolic Disorders Market Dynamics
8.1 Drugs for Metabolic Disorders Industry Trends
8.2 Drugs for Metabolic Disorders Market Drivers
8.3 Drugs for Metabolic Disorders Market Challenges
8.4 Drugs for Metabolic Disorders Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Drugs for Metabolic Disorders Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Drugs for Metabolic Disorders Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Drugs for Metabolic Disorders Market Competitive Situation by Manufacturers in 2022
Table 4. Global Drugs for Metabolic Disorders Sales (K Units) of Key Manufacturers (2018-2024)
Table 5. Global Drugs for Metabolic Disorders Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Drugs for Metabolic Disorders Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Drugs for Metabolic Disorders Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Drugs for Metabolic Disorders Average Price (USD/Unit) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Drugs for Metabolic Disorders, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Drugs for Metabolic Disorders, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Drugs for Metabolic Disorders, Product Type & Application
Table 12. Global Key Manufacturers of Drugs for Metabolic Disorders, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs for Metabolic Disorders by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Metabolic Disorders as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs for Metabolic Disorders Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Drugs for Metabolic Disorders Sales by Region (2018-2024) & (K Units)
Table 18. Global Drugs for Metabolic Disorders Sales Market Share by Region (2018-2024)
Table 19. Global Drugs for Metabolic Disorders Sales by Region (2024-2029) & (K Units)
Table 20. Global Drugs for Metabolic Disorders Sales Market Share by Region (2024-2029)
Table 21. Global Drugs for Metabolic Disorders Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Drugs for Metabolic Disorders Revenue Market Share by Region (2018-2024)
Table 23. Global Drugs for Metabolic Disorders Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Drugs for Metabolic Disorders Revenue Market Share by Region (2024-2029)
Table 25. North America Drugs for Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Drugs for Metabolic Disorders Sales by Country (2018-2024) & (K Units)
Table 27. North America Drugs for Metabolic Disorders Sales by Country (2024-2029) & (K Units)
Table 28. North America Drugs for Metabolic Disorders Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Drugs for Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Drugs for Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Drugs for Metabolic Disorders Sales by Country (2018-2024) & (K Units)
Table 32. Europe Drugs for Metabolic Disorders Sales by Country (2024-2029) & (K Units)
Table 33. Europe Drugs for Metabolic Disorders Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Drugs for Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Drugs for Metabolic Disorders Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Drugs for Metabolic Disorders Sales by Region (2018-2024) & (K Units)
Table 37. Asia Pacific Drugs for Metabolic Disorders Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Drugs for Metabolic Disorders Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Drugs for Metabolic Disorders Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Drugs for Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Drugs for Metabolic Disorders Sales by Country (2018-2024) & (K Units)
Table 42. Latin America Drugs for Metabolic Disorders Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Drugs for Metabolic Disorders Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Drugs for Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Drugs for Metabolic Disorders Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Drugs for Metabolic Disorders Sales by Country (2018-2024) & (K Units)
Table 47. Middle East & Africa Drugs for Metabolic Disorders Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Drugs for Metabolic Disorders Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Drugs for Metabolic Disorders Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Drugs for Metabolic Disorders Sales (K Units) by Type (2018-2024)
Table 51. Global Drugs for Metabolic Disorders Sales (K Units) by Type (2024-2029)
Table 52. Global Drugs for Metabolic Disorders Sales Market Share by Type (2018-2024)
Table 53. Global Drugs for Metabolic Disorders Sales Market Share by Type (2024-2029)
Table 54. Global Drugs for Metabolic Disorders Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Drugs for Metabolic Disorders Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Drugs for Metabolic Disorders Revenue Market Share by Type (2018-2024)
Table 57. Global Drugs for Metabolic Disorders Revenue Market Share by Type (2024-2029)
Table 58. Global Drugs for Metabolic Disorders Price (USD/Unit) by Type (2018-2024)
Table 59. Global Drugs for Metabolic Disorders Price (USD/Unit) by Type (2024-2029)
Table 60. Global Drugs for Metabolic Disorders Sales (K Units) by Application (2018-2024)
Table 61. Global Drugs for Metabolic Disorders Sales (K Units) by Application (2024-2029)
Table 62. Global Drugs for Metabolic Disorders Sales Market Share by Application (2018-2024)
Table 63. Global Drugs for Metabolic Disorders Sales Market Share by Application (2024-2029)
Table 64. Global Drugs for Metabolic Disorders Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Drugs for Metabolic Disorders Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Drugs for Metabolic Disorders Revenue Market Share by Application (2018-2024)
Table 67. Global Drugs for Metabolic Disorders Revenue Market Share by Application (2024-2029)
Table 68. Global Drugs for Metabolic Disorders Price (USD/Unit) by Application (2018-2024)
Table 69. Global Drugs for Metabolic Disorders Price (USD/Unit) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 73. Merck Drugs for Metabolic Disorders Product
Table 74. Merck Recent Developments/Updates
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 78. Novartis Drugs for Metabolic Disorders Product
Table 79. Novartis Recent Developments/Updates
Table 80. Takeda Pharmaceutical Corporation Information
Table 81. Takeda Pharmaceutical Description and Business Overview
Table 82. Takeda Pharmaceutical Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 83. Takeda Pharmaceutical Drugs for Metabolic Disorders Product
Table 84. Takeda Pharmaceutical Recent Developments/Updates
Table 85. Astra Zeneca Corporation Information
Table 86. Astra Zeneca Description and Business Overview
Table 87. Astra Zeneca Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 88. Astra Zeneca Drugs for Metabolic Disorders Product
Table 89. Astra Zeneca Recent Developments/Updates
Table 90. Boehringer Ingelheim Corporation Information
Table 91. Boehringer Ingelheim Description and Business Overview
Table 92. Boehringer Ingelheim Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 93. Boehringer Ingelheim Drugs for Metabolic Disorders Product
Table 94. Boehringer Ingelheim Recent Developments/Updates
Table 95. KOWA Corporation Information
Table 96. KOWA Description and Business Overview
Table 97. KOWA Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 98. KOWA Drugs for Metabolic Disorders Product
Table 99. KOWA Recent Developments/Updates
Table 100. Kythera Corporation Information
Table 101. Kythera Description and Business Overview
Table 102. Kythera Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 103. Kythera Drugs for Metabolic Disorders Product
Table 104. Kythera Recent Developments/Updates
Table 105. Fuji yakuhin Corporation Information
Table 106. Fuji yakuhin Description and Business Overview
Table 107. Fuji yakuhin Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 108. Fuji yakuhin Drugs for Metabolic Disorders Product
Table 109. Fuji yakuhin Recent Developments/Updates
Table 110. LG Life Science Corporation Information
Table 111. LG Life Science Description and Business Overview
Table 112. LG Life Science Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 113. LG Life Science Drugs for Metabolic Disorders Product
Table 114. LG Life Science Recent Developments/Updates
Table 115. Metsubishi Tanabe Pharma Corporation Information
Table 116. Metsubishi Tanabe Pharma Description and Business Overview
Table 117. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. Metsubishi Tanabe Pharma Drugs for Metabolic Disorders Product
Table 119. Metsubishi Tanabe Pharma Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Drugs for Metabolic Disorders Distributors List
Table 123. Drugs for Metabolic Disorders Customers List
Table 124. Drugs for Metabolic Disorders Market Trends
Table 125. Drugs for Metabolic Disorders Market Drivers
Table 126. Drugs for Metabolic Disorders Market Challenges
Table 127. Drugs for Metabolic Disorders Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Drugs for Metabolic Disorders
Figure 2. Global Drugs for Metabolic Disorders Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Drugs for Metabolic Disorders Market Share by Type in 2022 & 2029
Figure 4. Glycogen Metabolism Disease Drug Product Picture
Figure 5. Lipid Metabolism Disease Drug Product Picture
Figure 6. Amino Acid Metabolism Drug Product Picture
Figure 7. Other Product Picture
Figure 8. Global Drugs for Metabolic Disorders Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Drugs for Metabolic Disorders Market Share by Application in 2022 & 2029
Figure 10. Hospital
Figure 11. Retail Pharmacy
Figure 12. Global Drugs for Metabolic Disorders Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Drugs for Metabolic Disorders Market Size (2018-2029) & (US$ Million)
Figure 14. Global Drugs for Metabolic Disorders Sales (2018-2029) & (K Units)
Figure 15. Global Drugs for Metabolic Disorders Average Price (USD/Unit) & (2018-2029)
Figure 16. Drugs for Metabolic Disorders Report Years Considered
Figure 17. Drugs for Metabolic Disorders Sales Share by Manufacturers in 2022
Figure 18. Global Drugs for Metabolic Disorders Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Drugs for Metabolic Disorders Players: Market Share by Revenue in 2022
Figure 20. Drugs for Metabolic Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Drugs for Metabolic Disorders Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Drugs for Metabolic Disorders Sales Market Share by Country (2018-2029)
Figure 23. North America Drugs for Metabolic Disorders Revenue Market Share by Country (2018-2029)
Figure 24. the United States Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Drugs for Metabolic Disorders Sales Market Share by Country (2018-2029)
Figure 27. Europe Drugs for Metabolic Disorders Revenue Market Share by Country (2018-2029)
Figure 28. Germany Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. UK Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Drugs for Metabolic Disorders Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Drugs for Metabolic Disorders Revenue Market Share by Region (2018-2029)
Figure 35. China Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Drugs for Metabolic Disorders Sales Market Share by Country (2018-2029)
Figure 45. Latin America Drugs for Metabolic Disorders Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Drugs for Metabolic Disorders Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Drugs for Metabolic Disorders Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Drugs for Metabolic Disorders Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Drugs for Metabolic Disorders by Type (2018-2029)
Figure 55. Global Revenue Market Share of Drugs for Metabolic Disorders by Type (2018-2029)
Figure 56. Global Drugs for Metabolic Disorders Price (USD/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Drugs for Metabolic Disorders by Application (2018-2029)
Figure 58. Global Revenue Market Share of Drugs for Metabolic Disorders by Application (2018-2029)
Figure 59. Global Drugs for Metabolic Disorders Price (USD/Unit) by Application (2018-2029)
Figure 60. Drugs for Metabolic Disorders Value Chain
Figure 61. Drugs for Metabolic Disorders Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed